AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Abbott (NYSE: ABT) closed on August 18, 2025, with a 1.12% decline, trading at a volume of $0.50 billion, a 43.81% drop from the previous day’s activity. The stock ranked 182nd in trading volume among listed companies. Meanwhile, the healthcare giant launched its second annual "We Give Blood" campaign with the Big Ten Conference, aiming to address critical U.S. blood shortages by incentivizing donations through collegiate competition. The initiative, running from August 27 to December 5, 2025, pits all 18 Big Ten universities against one another, with the winning institution receiving $1 million to support student or community health programs.
Abbott’s campaign includes limited-edition T-shirts for participants and weekly challenges to engage fans, leveraging the competitive spirit of college athletics to drive first-time donations. The program follows the success of last year’s effort, which saw the University of Nebraska-Lincoln secure nearly 4,000 donations, potentially saving 12,000 lives. By aligning with Big Ten campuses and blood centers,
seeks to cultivate a new generation of lifelong donors while reinforcing its role in blood safety and diagnostics. The company emphasized that the campaign reflects a strategic investment in long-term healthcare infrastructure, addressing both immediate shortages and demographic shifts in donor demographics.The strategy of buying the top 500 stocks by daily trading volume and holding them for one day resulted in a moderate return. The total profit from this strategy, considering the given time frame from 2022 to the present, is $2,340. The cumulative return reaches 23.4%. This indicates a positive performance, but the returns are not significantly high, suggesting a more conservative approach to trading volume-based strategies.

Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Dec.30 2025

Dec.30 2025

Dec.29 2025

Dec.26 2025

Dec.26 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet